Liposome-based drug delivery of various anticancer agents of synthetic and natural product origin: a patent overview

Phospholipid-based liposomal vesicles are among the most effective delivery options currently available for various classes of anticancer drugs. The patents granted to inventions disclosing details on liposomal delivery module by the US Patent and Trademark Office, European Patent Office, and world...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical patent analyst 2020-05, Vol.9 (3), p.87-116
Main Authors: Akhtar, Naseem, Mohammed, Salman Aa, Singh, Varsha, Abdellatif, Ahmed Ah, Mohammad, Hamdoon A, Ahad, Abdul, Yusuf, Mohammad, Khadri, Habeeb, Naz, Mamuna, Khan, Omar, Rashid, Mohammad, Khan, Riaz A
Format: Article
Language:English
Subjects:
anticancer
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - metabolism
Bioavailability
Biological Products - administration & dosage
Biological Products - metabolism
Cancer
Drug Compounding - methods
drug delivery
Drug Delivery Systems - methods
Drugs
Humans
Intellectual property
Ligands
Lipids
liposome
Liposomes
Neoplasms - drug therapy
Neoplasms - metabolism
Oncology
Onsite
Patents as Topic - legislation & jurisprudence
Pharmaceutical industry
phospholipid vesicle
Phospholipids - administration & dosage
Phospholipids - metabolism
Researchers
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phospholipid-based liposomal vesicles are among the most effective delivery options currently available for various classes of anticancer drugs. The patents granted to inventions disclosing details on liposomal delivery module by the US Patent and Trademark Office, European Patent Office, and world patent holdings through WIPO (World Intellectual Property Organization) patenting have been sorted based upon liposome, and anticancer keywords within the abstract and claims sections of the patents for the period between 2000 and 2019, thereby disclosing novel liposome formulations encapsulating single, or combination of chemotherapeutic agents that have been far more chemically and physiologically stable, therapeutically efficacious, and comparatively less toxic than their nonliposomal free-drug counterparts. The added stability, site-specific transport, and payload delivery, enhanced bioavailability, fast body clearance, and biocompatibility together with the controlled and sustained delivery-related benefits claimed in the patent literature have been exclusively discussed with a focus on the last 5-year period.
ISSN:2046-8954
2046-8962
DOI:10.4155/ppa-2019-0020